嗜铬细胞瘤 中国就医指南

Pheochromocytoma is a rare, usually benign neuroendocrine tumor arising from chromaffin cells of the adrenal medulla. It secretes excessive amounts of catecholamines—primarily epinephrine and norepinephrine—leading to episodic or sustained hypertension, tachycardia, severe headaches, diaphoresis, palpitations, anxiety, and pallor. Though most cases (≈90%) are sporadic, up to 40% are associated with hereditary syndromes including multiple endocrine neoplasia type 2 (MEN2), von Hippel–Lindau (VHL) disease, neurofibromatosis type 1 (NF1), and succinate dehydrogenase (SDHx) gene mutations. Pathogenesis involves dysregulated catecholamine synthesis and secretion due to somatic or germline mutations in genes governing cellular metabolism, hypoxia signaling, and kinase pathways (e.g., RET, VHL, NF1, SDHB). Epidemiologically, pheochromocytoma affects approximately 2–8 per million people annually, with peak incidence between ages 30–50; it accounts for <0.2% of secondary hypertension cases. Both sexes are equally affected, and bilateral or extra-adrenal (paraganglioma) variants occur in ~10–15% of cases. Key risk factors include family history of hereditary cancer syndromes, prior radiation exposure (rare), and specific germline mutations—especially SDHB, which confers higher malignancy risk (up to 30–50%). Untreated or misdiagnosed pheochromocytoma poses life-threatening risks: hypertensive crises, stroke, myocardial infarction, heart failure, and sudden death. Even after successful resection, patients may experience persistent autonomic dysfunction, medication-dependent blood pressure lability, fatigue, and anxiety—significantly impairing daily functioning, work capacity, and emotional well-being. Quality of life impact is profound: chronic symptom burden, diagnostic delays (average 3–5 years), fear of crisis episodes, and lifelong surveillance requirements contribute to high psychological distress, reduced social engagement, and diminished health-related quality of life (HRQoL) scores across physical, role, and mental domains. Early diagnosis via plasma-free metanephrines or 24-hour urinary fractionated metanephrines—followed by anatomical (CT/MRI) and functional (123I-MIBG or 68Ga-DOTATATE PET/CT) imaging—is critical. Preoperative alpha-adrenergic blockade (e.g., phenoxybenzamine or doxazosin) for ≥10–14 days is mandatory to prevent intraoperative hypertensive emergencies. Surgical resection—typically laparoscopic adrenalectomy—is the definitive treatment and curative in >95% of benign cases. Lifelong annual biochemical screening is recommended, especially for hereditary cases, due to recurrence or new tumor development risk.

# 嗜铬细胞瘤治疗方案与费用明细（内分泌科）

一、药物保守治疗（术前准备及无法手术者）

• •适用人群：血压控制不佳、高危手术患者、肿瘤转移或拒绝手术者
• •核心方案：α受体阻滞剂（酚苄明）+ β受体阻滞剂（普萘洛尔，仅在α阻滞后启用）+ 补液扩容
• •费用明细（30天周期）：

- 监测检查费：24h尿儿茶酚胺、血浆游离甲氧基肾上腺素（MN/ NMN）、心电监护、卧立位血压监测等：1,200–2,800元

二、手术根治方案（首选治疗）

• •适用条件：定位明确、无远处转移、心功能可耐受麻醉
• •术式选择：腹腔镜肾上腺切除（95%首选）、开放手术（巨大/侵袭性肿瘤）
• •全套费用区间：

- 手术+住院（7–10天）：32,000–68,000元（含微创耗材、病理、ICU过渡监护）

三、特殊复杂情况处理

• •恶性/转移性/复发性：131I-MIBG治疗、肽受体放射性核素治疗（PRRT）、靶向药（替莫唑胺±贝伐珠单抗）：单周期8–25万元，需多学科会诊（MDT）确认适应证

四、方案快速选择指南

• •预算有限且病情稳定：优选药物控制+定期随访（年均约5,000元）
• •确诊早期、无禁忌：腹腔镜手术为根治金标准（推荐一次性投入）
• •转移/复发/高龄高危：转入内分泌科MDT团队制定个体化综合方案